Compare · RMD vs TMCI
RMD vs TMCI
Side-by-side comparison of ResMed Inc. (RMD) and Treace Medical Concepts Inc. (TMCI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and TMCI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.86B, about 103.5x TMCI ($279.0M).
- RMD has hit the wire 7 times in the past 4 weeks while TMCI has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 19 for TMCI).
- Company
- ResMed Inc.
- Treace Medical Concepts Inc.
- Price
- -
- -
- Market cap
- $28.86B
- $279.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 19
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Treace Medical Concepts Inc.
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was incorporated in 2014 and is headquartered in Ponte Vedra Beach, Florida.
Latest RMD
- ResMed downgraded by RBC Capital Mkts with a new price target
- ResMed downgraded by Citigroup with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Resmed Announces Agreement to Sell MatrixCare Business
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
- ResMed downgraded by Morgan Stanley with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
Latest TMCI
- Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System
- Sidoti Events, LLC's June Small-Cap Virtual Conference
- Amendment: Chief Executive Officer Treace John T. bought $99,196 worth of shares (24,606 units at $4.03), increasing direct ownership by 0.34% to 7,348,439 units (SEC Form 4)
- Chief Executive Officer Treace John T. bought $210,968 worth of shares (52,317 units at $4.03), increasing direct ownership by 0.71% to 7,376,150 units (SEC Form 4)
- Treace to Present at the Sidoti Small Cap Conference
- Chief Executive Officer Treace John T. bought $177,915 worth of shares (50,000 units at $3.56), increasing direct ownership by 0.69% to 7,323,833 units (SEC Form 4)
- Chief Executive Officer Treace John T. bought $340,589 worth of shares (115,520 units at $2.95), increasing direct ownership by 2% to 7,273,833 units (SEC Form 4)
- Treace Medical Concepts Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Jain Deepti was granted 30,000 shares, increasing direct ownership by 43% to 100,243 units (SEC Form 4)
- Director Bakewell John K was granted 30,000 shares, increasing direct ownership by 17% to 204,056 units (SEC Form 4)